-
2024-520068-32-00
6
Type 2 diabetes
-
2025-521221-32-00
5
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2025-522377-12-00
5
metastatic colorectal cancer
-
2025-522484-15-00
5
2026-04-27
ER+/HER2- early breast cancer
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2024-517573-24-00
4
2025-12-08
Colorectal cancer
-
2024-519929-38-00
4
2025-10-27
Metastatic Colorectal Cancer without liver metastases
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-516633-12-00
5
2025-06-30
Locally advanced/ metastatic gastroesophageal junction and gastric can
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2023-508076-11-00
5
2025-04-01
Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
-
2024-514304-14-00
1
2024-10-08
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
-
2023-505436-35-00
5
2024-06-03
Untreated FLIPI 2-5 Follicular Lymphoma
-
2022-502046-28-00
5
2023-12-22
HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
-
2022-501810-77-00
5
2023-09-01
Relapsed or Refractory Marginal Zone Lymphoma
-
2022-501187-18-00
5
2023-04-24
a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2022-500764-35-00
6
2022-10-13
Patients with advanced HER2-negative, hormone receptor positive (HER2n
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-513723-16-00
4
2021-10-21
metastatic colorectal cancer
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer